Aditi A. Sharma

Aditi A. Sharma

Auto-generated profile, based on publicly available information

Aditi A. Sharma

University of California, Irvine

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2017 in Clinics in Dermatology
Verified
Journal Article
Closed access
JLJames L. Levenson
James L. Levenson
ASAditi A. Sharma
Aditi A. Sharma
ALAlex Ortega Loayza
Alex Ortega Loayza

12 January 2021 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
ASAditi A. Sharma
Aditi A. Sharma
KLKachiu C. Lee
Kachiu C. Lee
LGLilit Garibyan
Lilit Garibyan

21 September 2020 in Ear, Nose & Throat Journal
Verified
Journal Article
Open access
PDF file
SSSamantha Shwe
Samantha Shwe
ASAditi A. Sharma
Aditi A. Sharma
BLBonnie A. Lee
Bonnie A. Lee
JSJanellen E. Smith
Janellen E. Smith
Plasmablastic lymphoma (PBL) is a rare type of non-Hodgkin lymphoma frequently found in the context of immunosuppression and infection with human immunodeficiency virus (HIV) and/or Epstein-Barr virus (EBV). A 33-year-old immunocompetent male presented with recurrent episodes of epistaxis and a growing intranasal mass. Excisional biopsy of the mass revealed an immunohistochemical profile diagnostic of PBL. Upon completion of chemoradiation, he underwent a transnasal endoscopic mucosal flap tissue rearrangement to restore patency for both functional and surveillance purposes. There was no endoscopic evidence of residual or recurrent disease. However, 8 months later, he was found to have a relapse involving the skin. The nasal cavity is one of the most common sites affected by PBL. Involvement of the nasal cavity may present with symptoms of persistent epistaxis accompanied by an enlarging mass. A plasmablastic immunophenotype in combination with HIV or EBV positivity can aid diagnosis.

28 October 2026 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
RMRongwei Mao
Rongwei Mao
SYShengshuo Yan
Shengshuo Yan
ASAditi A. Sharma
Aditi A. Sharma
TSTony Shum
Tony Shum
YZYang Zhang
Yang Zhang
Background: Noninvasive radiofrequency (RF) therapy has emerged as a prominent approach for facial rejuvenation due to its ability to stimulate collagen remodeling without epidermal ablation. However, conventional RF systems often rely on high thermal output, posing risks of heat‐induced dermal damage. Objective: This study aimed to evaluate the safety and efficacy of a novel micro‐RF device (nebulyft), utilizing a high‐density 321‐electrode MEMS array designed to deliver high precision low‐power phase‐controlled RF energy for facial wrinkle reduction and improved skin texture. Methods: In this prospective, open‐label clinical trial, 42 participants from California, USA (age 29–62, Fitzpatrick skin types II–IV) completed a 4‐week treatment protocol using the nebulyft device. Each subject underwent one supervised clinic‐based session, followed by at‐home treatments (16 min per session, ≥ 5 sessions per week). Efficacy was assessed using the Fitzpatrick Wrinkle Severity Scale (FWSS) by three blinded board‐certified dermatologists, and subject satisfaction was recorded via a 4‐point Likert scale. Results: At one‐month post‐treatment visit, 90.5% of participants in the primary FAS (38/42) met the ≥ 1‐point FWSS responder criterion; the supportive PPS result was 92.7% (38/41), as determined by at least two blinded evaluators (FAS exact one‐sided p = 0.0015 vs. the prespecified 70% performance goal). The mean subject satisfaction score was 15.76 ± 0.54 out of 16. No pain was reported by any participant during treatment sessions. No adverse events, discomfort, or device malfunctions were reported.

1 September 2021 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
PDF file
SSSamantha Shwe
Samantha Shwe
ASAditi A. Sharma
Aditi A. Sharma
PLPatrick K. Lee
Patrick K. Lee